Search research articles
Contact Us
Filters
Showing results (1-10 of 18) with videos related to
Page
of 2
Sort By:
Antimicrobial Agents and Chemotherapy
|
April 13, 2013
Reply to "Vancomycin-induced nephrotoxicity"
S J van Hal, D L Paterson, T P Lodise
Antimicrobial Agents and Chemotherapy
|
November 21, 2012
Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter
S J van Hal, D L Paterson, T P Lodise
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 4, 2012
The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis
S J van Hal, T P Lodise, D L Paterson
Antimicrobial Agents and Chemotherapy
|
October 28, 2009
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients
N Patel, M H Scheetz, G L Drusano, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Efficacy and Hospitalization Length of Stay of Single Dose Oritavancin Compared to 7-10 Days of Vancomycin in Patients with Acute Bacterial Skin and Skin Structure Infections in the Us and Eastern Europe
K LaPensee, W Fan, C Fiset, et al.
Antimicrobial Agents and Chemotherapy
|
January 19, 2012
Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function
T P Lodise, J M Butterfield, S S Hegde, et al.
Antimicrobial Agents and Chemotherapy
|
February 9, 2011
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia
T P Lodise, F Sorgel, D Melnick, et al.
The Journal of Antimicrobial Chemotherapy
|
September 6, 2007
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation
T P Lodise, R Nau, M Kinzig, et al.
Antimicrobial Agents and Chemotherapy
|
September 18, 2013
Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin
T P Lodise, N Patel, A Rivera, et al.
Antimicrobial Agents and Chemotherapy
|
July 2, 2008
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
T P Lodise, J Graves, A Evans, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 18) with videos related to
Sort By:
Page
of 2
Antimicrobial Agents and Chemotherapy
|
April 13, 2013
Reply to "Vancomycin-induced nephrotoxicity"
S J van Hal, D L Paterson, T P Lodise
Antimicrobial Agents and Chemotherapy
|
November 21, 2012
Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter
S J van Hal, D L Paterson, T P Lodise
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
February 4, 2012
The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis
S J van Hal, T P Lodise, D L Paterson
Antimicrobial Agents and Chemotherapy
|
October 28, 2009
Identification of optimal renal dosage adjustments for traditional and extended-infusion piperacillin-tazobactam dosing regimens in hospitalized patients
N Patel, M H Scheetz, G L Drusano, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
May 21, 2016
Efficacy and Hospitalization Length of Stay of Single Dose Oritavancin Compared to 7-10 Days of Vancomycin in Patients with Acute Bacterial Skin and Skin Structure Infections in the Us and Eastern Europe
K LaPensee, W Fan, C Fiset, et al.
Antimicrobial Agents and Chemotherapy
|
January 19, 2012
Telavancin pharmacokinetics and pharmacodynamics in patients with complicated skin and skin structure infections and various degrees of renal function
T P Lodise, J M Butterfield, S S Hegde, et al.
Antimicrobial Agents and Chemotherapy
|
February 9, 2011
Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia
T P Lodise, F Sorgel, D Melnick, et al.
The Journal of Antimicrobial Chemotherapy
|
September 6, 2007
Pharmacodynamics of ceftazidime and meropenem in cerebrospinal fluid: results of population pharmacokinetic modelling and Monte Carlo simulation
T P Lodise, R Nau, M Kinzig, et al.
Antimicrobial Agents and Chemotherapy
|
September 18, 2013
Comparative evaluation of serotonin toxicity among veterans affairs patients receiving linezolid and vancomycin
T P Lodise, N Patel, A Rivera, et al.
Antimicrobial Agents and Chemotherapy
|
July 2, 2008
Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin
T P Lodise, J Graves, A Evans, et al.
Page
of 2